Boyce & Associates Wealth Consulting’s AbbVie ABBV Stock Holding History

Boyce & Associates Wealth Consulting’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$351K	Buy	1,395 +10	+0.7%	+$2.15K	0.24%	59
2026 Q1	$301K	Buy	1,385 +153	+12%	+$33.9K	0.23%	62
2025 Q4	$282K	Sell	1,232 -42	-3%	-$9.57K	0.24%	59
2025 Q3	$295K	Buy	1,274 +10	+0.8%	+$2.04K	0.24%	56
2025 Q2	$235K	Buy	1,264 +11	+0.9%	+$2.04K	0.21%	66
2025 Q1	$263K	Buy	1,253 +1	+0.1%	+$194	0.26%	57
2024 Q4	$222K	Buy	1,252 +1	+0.1%	+$184	0.23%	66
2024 Q3	$247K	Buy	1,251 +2	+0.2%	+$373	0.26%	64
2024 Q2	$214K	Buy	1,249 +1	+0.1%	+$166	0.25%	64
2024 Q1	$227K	Buy	+1,248	New	+$215K	0.29%	53
2023 Q2	–	Sell	-1,274	Closed	-$206K	–	49
2023 Q1	$206K	Buy	1,274 +34	+3%	+$5.2K	0.37%	47
2022 Q4	$200K	Buy	+1,240	New	+$190K	0.38%	44
2022 Q2	–	Sell	-1,236	Closed	-$200K	–	48
2022 Q1	$200K	Buy	+1,236	New	+$180K	0.3%	51

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Boyce & Associates Wealth Consulting's ABBV Position: Q2 2026 in Review

Boyce & Associates Wealth Consulting increased its AbbVie (ABBV) stake by 0.72% in Q2 2026, buying an estimated $2.15K and bringing the position to 1,395 shares worth $351K. The position accounts for 0.24% of the portfolio, ranked #59.

Boyce & Associates Wealth Consulting first reported a position in ABBV in Q1 2022 and has held it in 13 quarters since. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Boyce & Associates Wealth Consulting held 1,395 shares of AbbVie worth $351K as of Q2 2026.
Boyce & Associates Wealth Consulting bought 10 AbbVie shares in Q2 2026, an estimated $2.15K.
AbbVie made up 0.24% of Boyce & Associates Wealth Consulting's portfolio in Q2 2026, its #59 holding.
Boyce & Associates Wealth Consulting first reported a position in AbbVie in Q1 2022 and has held it in 13 quarters since.
4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Boyce & Associates Wealth Consulting's 13F filing for Q2 2026, filed 23 Jul 2026.